Roland Heinig

A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

K. Mross, Annette Frost, Simone Steinbild et al. · Clinical Cancer Research · 2012 · 333 citations

Medicine, Oncology, Pharmacology +17

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

Dirk Strumberg, M. E. Scheulen, Beate Schultheis et al. · British Journal of Cancer · 2012 · 254 citations · Full text

Medicine, Oncology, Pharmacology +16

Capillary electrophoresis with laser-induced fluorescence: a routine method to determine moxifloxacin in human body fluids in very small sample volumes

Jan G. Möller, Heino Staß, Roland Heinig et al. · Journal of Chromatography B Biomedical Sciences and Applications · 1998 · 94 citations

Pharmacy, Pharmaceutical Analysis, Pharmacology +9

Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro

Michael Gerisch, Roland Heinig, Anna Engelen et al. · Drug Metabolism and Disposition · 2018 · 73 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacology +13

Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94–8862) in Individuals With Renal Impairment

Roland Heinig, Nina Kimmeskamp‐Kirschbaum, Atef Halabi et al. · Clinical Pharmacology in Drug Development · 2016 · 67 citations

Pharmacy, Pharmacokinetics, Pharmacology +17